Searchable abstracts of presentations at key conferences in endocrinology

ea0052p23 | (1) | UKINETS2017

Above-label doses of lanreotide Autogel for the treatment of advanced neuroendocrine tumours (NETs)

Laskaratos Faidon-Marios , Banks Jamie , Shah Ruchir , Smith Jack , Jacobs Ben , Galanopoulos Michalis , Caplin Martyn , Mandair Dalvinder , Toumpanakis Christos

Introduction: High doses/frequency of somatostatin analogues (SSA) are often used to control refractory functional symptoms and/or tumour progression in patients treated with standard doses of SSAs, but there is limited evidence for the efficacy of this strategy.Methods: Retrospective analysis of 47 NET patients on lanreotide Autogel 120 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change i...

ea0051p027 | Miscellaneous/other | BSPED2017

Is there an association between endocrine conditions, including growth hormone deficiency, and Chiari-1 Malformation? A retrospective single centre study

Elhag Sabba , Shah Jamie , Krone Ruth , Kershaw Melanie , Shaw Nick , Barrett Timothy , Kirk Jeremy , Saraff Vrinda , Hogler Wolfgang , Solanki Guirish , Dias Renuka

Introduction: Chiari-1 malformation (C-1M) is defined as the crowding of the craniocervical junction as a result of congenital cerebellar tonsil descent past the foramen magnum. Reported association between endocrine disorders and C-1M is mostly anecdotal.Aims: To evaluate the prevalence of endocrine disorders in C-1M against the prevalence of C-1M in those with isolated Growth Hormone Deficiency (GHD) with the aim of determining if there is a significan...